CL2021002430A1 - Formulación de tableta vaginal - Google Patents

Formulación de tableta vaginal

Info

Publication number
CL2021002430A1
CL2021002430A1 CL2021002430A CL2021002430A CL2021002430A1 CL 2021002430 A1 CL2021002430 A1 CL 2021002430A1 CL 2021002430 A CL2021002430 A CL 2021002430A CL 2021002430 A CL2021002430 A CL 2021002430A CL 2021002430 A1 CL2021002430 A1 CL 2021002430A1
Authority
CL
Chile
Prior art keywords
tablet formulation
vaginal tablet
vaginal
glucono
lactone
Prior art date
Application number
CL2021002430A
Other languages
English (en)
Inventor
Ulf Ellervik
Olov Sterner
Helena Strevens
Sophie Manner
Nils-Olof Lindberg
Annette Säfholm
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of CL2021002430A1 publication Critical patent/CL2021002430A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende glucono-d-lactona, que es adecuada para uso en el tratamiento de infecciones microbianas vaginales.
CL2021002430A 2019-04-05 2021-09-20 Formulación de tableta vaginal CL2021002430A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19167495 2019-04-05

Publications (1)

Publication Number Publication Date
CL2021002430A1 true CL2021002430A1 (es) 2022-07-01

Family

ID=66101895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002430A CL2021002430A1 (es) 2019-04-05 2021-09-20 Formulación de tableta vaginal

Country Status (24)

Country Link
US (1) US20220193031A1 (es)
EP (1) EP3976000B1 (es)
JP (1) JP2022537478A (es)
KR (1) KR20210148195A (es)
CN (1) CN113660928B (es)
AR (1) AR118580A1 (es)
AU (1) AU2020252268A1 (es)
BR (1) BR112021019999A2 (es)
CA (1) CA3134086A1 (es)
CL (1) CL2021002430A1 (es)
CO (1) CO2021014253A2 (es)
EA (1) EA202192716A1 (es)
ES (1) ES2961736T3 (es)
HU (1) HUE062772T2 (es)
IL (1) IL286942B1 (es)
MA (1) MA56011A (es)
MX (1) MX2021012146A (es)
PE (1) PE20220381A1 (es)
PL (1) PL3976000T3 (es)
SG (1) SG11202110236QA (es)
TW (1) TWI846854B (es)
UA (1) UA127823C2 (es)
WO (1) WO2020201515A1 (es)
ZA (1) ZA202106877B (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA90341B (en) * 1989-01-23 1990-10-31 Merrell Dow Pharma Liquid pharmaceutical composition for piperidinoalkanol derivatives
DE69802260T2 (de) * 1998-04-30 2002-07-04 Renata Maria Anna Cavaliere Vesely Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20050175694A1 (en) * 2002-04-23 2005-08-11 Himadri Sen Long acting compositions comprising zidovudine and lamivudine
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
MY198473A (en) 2016-04-06 2023-08-31 Gedea Biotech Ab Glucono delta-lactone for treatment of vaginal fungal infections
JP7424636B2 (ja) 2017-10-06 2024-01-30 ジェディア バイオテック エービー 微生物感染症の治療および／または予防用グルコン酸誘導体

Also Published As

Publication number Publication date
CN113660928A (zh) 2021-11-16
CO2021014253A2 (es) 2021-11-19
IL286942B1 (en) 2024-09-01
CN113660928B (zh) 2024-04-05
IL286942A (en) 2021-12-01
EP3976000B1 (en) 2023-08-02
JP2022537478A (ja) 2022-08-26
MA56011A (fr) 2022-04-06
EP3976000C0 (en) 2023-08-02
CA3134086A1 (en) 2020-10-08
BR112021019999A2 (pt) 2021-12-07
ZA202106877B (en) 2023-03-29
PE20220381A1 (es) 2022-03-18
US20220193031A1 (en) 2022-06-23
EA202192716A1 (ru) 2022-01-17
HUE062772T2 (hu) 2023-12-28
ES2961736T3 (es) 2024-03-13
AU2020252268A1 (en) 2021-10-21
AR118580A1 (es) 2021-10-20
MX2021012146A (es) 2021-12-10
UA127823C2 (uk) 2024-01-10
SG11202110236QA (en) 2021-10-28
EP3976000A1 (en) 2022-04-06
WO2020201515A1 (en) 2020-10-08
PL3976000T3 (pl) 2023-12-04
KR20210148195A (ko) 2021-12-07
TWI846854B (zh) 2024-07-01
TW202103693A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
DOP2017000038A (es) 2-(morfolin-4-il)-1,7-naftiridinas
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
NI201500048A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CO2020001242A2 (es) Dihidrooxadiazinonas
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
NI201900063A (es) Amidas aromáticas de ácido carboxílico
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
CO2019011305A2 (es) Tratamiento de una infección vaginal bacteriana
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CL2021002430A1 (es) Formulación de tableta vaginal
MX2020004105A (es) Formulacion farmaceutica.
CU20200020A7 (es) Composición farmacéutica que comprende abx196
PL425327A1 (pl) Zastosowanie α,β,2',3'-tetrahydroksantohumolu